Tobira Therapeutics
Tobira Therapeutics
Tobira Therapeutics
Tobira Therapeutics
Tobira Therapeutics
Tobira Therapeutics
Tobira Therapeutics
Tobira Therapeutics
Tobira Therapeutics
Tobira Therapeutics
Tobira Therapeutics
Tobira Therapeutics Tobira Therapeutics Tobira Therapeutics
Tobira Therapeutics acquires, develops and commercializes innovative products for the treatment of important and unmet medical needs in infectious diseases such as HIV/AIDS, hepatitis, and other associated infectious conditions. At Tobira, we are committed to creating value for patients, healthcare providers and other important stakeholders by building a world-class team, accelerating the development of our lead product candidate and expanding our pipeline through acquisitions and alliances.
Tobira Therapeutics
Tobira Therapeutics Join The Tobira Email List
Tobira Therapeutics
Tobira Therapeutics Product Pipeline
Tobira Therapeutics
 

TOBIRA ANNOUNCES

7.19.10
Tobira IAC Oral Presentation –TBR-652, A Potent Dual Chemokine Receptor 5/Chemokine Receptor 2 (CCR5/CCR2) Antagonist in Phase 2 Development for Treatment of HIV Infection

7.19.10
Tobira IAC Press Release - TOBIRA’S NEXT-GENERATION ONCE-DAILY CCR5/CCR2 ANTAGONIST DEMONSTRATES POTENT CCR2 INHIBITION, ANTIVIRAL ACTIVITY, SAFETY AND TOLERABILITY IN TREATMENT-EXPERIENCED PATIENTS WITH HIV; TBR-652 Phase IIa Data Presented at XVIII International AIDS Conference Showcase Potentially Important Anti-Inflammatory Benefits

Tobira Therapeutics
Tobira Therapeutics
  Digital Endeavor Websites